Caribou Biosciences, INC 8-K filings

Caribou Biosciences, Inc. reported the results of its annual meeting of stockholders held on June 17, 2026, including the election of directors and ratification of its accounting firm.

Caribou Biosciences announced updated clinical trial data for its vispa-cel and CB-011 CAR-T cell therapies, showing durable responses in patients with B-NHL and multiple myeloma.

Caribou Biosciences announced its allogeneic anti-BCMA CAR-T cell therapy, CB-011, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for relapsed or refractory multiple myeloma.

Caribou Biosciences reported its fourth quarter and full year 2025 financial results, highlighting strong clinical progress for its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011.

Caribou Biosciences announced positive clinical data for its CAR-T cell therapies vispa-cel and CB-011, alongside its third quarter 2025 financial results.

Caribou Biosciences announced positive preliminary financial results and compelling clinical data from its ANTLER and CaMMouflage Phase 1 trials for allogeneic CAR-T cell therapies vispa-cel and CB-011.

Caribou Biosciences announced second quarter 2025 financial results and positive clinical updates for its allogeneic CAR-T programs, CB-010 and CB-011.

Caribou Biosciences, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a potential delisting issue.

Caribou Biosciences, Inc. announced the results of its annual meeting, where stockholders approved a potential reverse stock split, re-elected two Class I directors, and ratified Deloitte & Touche LLP as its independent auditor.

Caribou Biosciences announced its Q1 2025 financial results and provided a business update, highlighting upcoming data disclosures for its lead oncology programs and an extended cash runway.

Caribou Biosciences announces strategic pipeline prioritization, workforce reduction, and provides a cash update, extending its financial runway into the second half of 2027.

Caribou Biosciences announces positive clinical trial updates and financial results for Q4 and full year 2024, with cash runway extended into H2 2026.

Caribou Biosciences has initiated a Phase 1 trial for lupus, highlighted progress in its CAR-T cell therapy programs, and anticipates multiple clinical data readouts in 2025.

Caribou Biosciences has appointed Sriram Ryali as its new Chief Financial Officer, effective January 2, 2025.

Caribou Biosciences announced its third quarter 2024 financial results and provided updates on its clinical-stage programs, highlighting progress in multiple myeloma and lupus trials.

Caribou Biosciences has appointed Ryan Fischesser as interim principal financial officer and principal accounting officer, effective September 27, 2024, following the resignation of Jason OByrne.

Caribou Biosciences' Chief Financial Officer, Jason O'Byrne, has resigned effective September 27, 2024, and will be succeeded as principal accounting officer by Ryan Fischesser.

Caribou Biosciences has appointed Tina Albertson, a highly experienced hematologist and oncologist, as its new Chief Medical Officer.

Caribou Biosciences announced its second quarter 2024 financial results, highlighting progress in its clinical-stage programs and extending its cash runway into the second half of 2026.

Caribou Biosciences has discontinued its allogeneic CAR-NK platform research, reduced its workforce by 12%, and expects to extend its cash runway into the second half of 2026.

Caribou Biosciences held its annual meeting of stockholders on June 13, 2024, where key proposals including the election of directors and ratification of the accounting firm were approved.

Caribou Biosciences announced updated clinical data from its ANTLER Phase 1 trial showing that CB-010, an allogeneic CAR-T cell therapy, demonstrates potential to rival autologous CAR-T therapies, particularly with partial HLA matching.

Caribou Biosciences announced its first quarter 2024 financial results and provided updates on its clinical programs, including upcoming data presentations and trial initiations.

Caribou Biosciences has received FDA clearance for its investigational new drug application for CB-010, an allogeneic CAR-T cell therapy, to treat lupus nephritis and extrarenal lupus, expanding its clinical development beyond oncology.

Caribou Biosciences announces positive progress in its clinical trials and a strong cash position to fund operations into Q1 2026.